Smallpox: all 74 studies
Page 1 of 1. Open to participants first (5), then studies with results posted, then the rest; newest registration first within each.
- A Randomized Clinical Trial Investigating the Safety, Reactogenicity, and Immunogenicity After Immunization With an mRNA-based Mpox Vaccine Candidate in AfricaRecruitingNCT07379580Phase 2
- Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BSY001 After Single/Multiple Doses.RecruitingNCT07377175Phase 1
- Assessment of Myocarditis After Replication-Deficient Smallpox ImmunizationNot yet recruitingNCT05513313
- Tecovirimat (ST-246) Treatment for Orthopox Virus ExposureAvailableNCT02080767
- VA-005 Clinical Outcomes of VIGIV Treatment of Smallpox Vaccination Complications or Vaccinia InfectionEnrolling by invitationNCT01374984
- Safety, Tolerability and Pharmacokinetics of TPOXX When Administered Orally for 28 DaysCompletedNCT04971109Phase 3Results posted
- Drug-drug Interaction Study of TPOXX When Co-administered With Phosphate BindersCompletedNCT04485039Phase 4Results posted
- Safety, Tolerability and PK of TPOXX in Adults Weighing More Than 120 KGCompletedNCT04392739Phase 4Results posted
- Freeze-Dried MVA-BN® Lot Consistency Smallpox TrialCompletedNCT03699124Phase 3Results posted
- A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of the Anti-Orthopoxvirus Compound TecovirimatCompletedNCT02474589Phase 3Results posted
- VA-008 ACAM2000® Vaccination of Plasma Donors for the Production of VIGIVCompletedNCT02443623Phase 4Results posted
- Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV InfectionCompletedNCT02038881Phase 2Results posted
- Phase II Trial to Assess Safety and Immunogenicity of IMVAMUNE®CompletedNCT01827371Phase 2Results posted
- A Phase II Trial to Compare a Liquid-frozen and a Freeze-dried Formulation of IMVAMUNE (MVA-BN®) Smallpox Vaccine in Vaccinia-naïve Healthy SubjectsCompletedNCT01668537Phase 2Results posted
- VA-006 Vaccinia Vaccine (ACAM2000) for the Production of VIGIVCompletedNCT01158157Phase 3Results posted
- A Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in Healthy, Vaccinia-naïve SubjectsCompletedNCT01144637Phase 3Results posted
- Lyophilized IMVAMUNE® (1x10^8 TCID50) Versus Liquid IMVAMUNE® (1x10^8 TCID50) Administered Subcutaneously and a Lower Dose Liquid IMVAMUNE® (2x10^7 TCID50) Administered IntradermallyCompletedNCT00914732Phase 2Results posted
- Safety, Tolerability, Pharmacokinetics (PK) of the Anti-Orthopox Drug, ST-246CompletedNCT00907803Phase 2Results posted
- High Dose IMVAMUNE® in Vaccinia-Naive IndividualsCompletedNCT00879762Phase 2Results posted
- A Study to Evaluate Safety and Immunogenicity of One and Two Doses of IMVAMUNE® Smallpox Vaccine in 56-80 Year Old Vaccinia-experienced SubjectsCompletedNCT00857493Phase 2Results posted
- Phase I Trial of an Investigational Small Pox MedicationCompletedNCT00728689Phase 1Results posted
- An Open-Label Phase II Study to Evaluate Immunogenicity and Safety of a Single IMVAMUNE Booster Vaccination Two Years After the Last IMVAMUNE Vaccination in Former POX-MVA-005 VaccineesCompletedNCT00686582Phase 2Results posted
- Safety and Efficacy of CJ-50300 in Healthy VolunteersCompletedNCT00607243Phase 2/3Results posted
- MVA Post-Event: Administration Timing and Boost StudyCompletedNCT00437021Phase 1/2Results posted
- A Phase II Study on Immunogenicity and Safety of MVA-BN® (IMVAMUNE™) Smallpox Vaccine in Subjects With Atopic DermatitisCompletedNCT00316602Phase 2Results posted
- Safety and Immunogenicity of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in HIV Infected PatientsCompletedNCT00316589Phase 2Results posted
- A Randomized, Double-blind, Placebo-controlled Study on Immunogenicity and Safety of MVA-BN (IMVAMUNE™) Smallpox Vaccine in Healthy SubjectsCompletedNCT00316524Phase 2Results posted
- ACAM 3000 MVA at Harvard Medical SchoolCompletedNCT00133575Phase 1/2Results posted
- Effect of Dose, Safety, Tolerability of a New Smallpox Vaccine in Adults Without Previous Smallpox VaccinationCompletedNCT00053495Phase 2Results posted
- Dose Study of ACAM2000 Smallpox Vaccine in Previously Vaccinated AdultsCompletedNCT00053482Phase 2Results posted
- Phase 3 Maternal Safety & Immunogenicity Trial of MVA-BN® in DRCActive, not recruitingNCT06844500Phase 3
- Phase 3 Infant Safety & Immunogenicity Trial of MVA-BN® in DRCActive, not recruitingNCT06844487Phase 3
- A Study to Investigate The Safety, Tolerability, And Immune Response of a Range of Doses of mRNA-1769 Compared With Placebo in Healthy Participants From ≥18 Years of Age to <50 Years of AgeCompletedNCT05995275Phase 1/2
- Study of the Safety, Tolerability, Pharmacokinetics of NIOCH-14 in Volunteers Aged 18-50 YearsCompletedNCT05976100Phase 1
- Study Evaluating the Bioequivalence of Brincidofovir Form H and Form II Tablets in Healthy AdultsCompletedNCT05935917Phase 1
- Study on Immunogenicity, Reactogenicity and Safety of the VACΔ6 Vaccine in Volunteers Aged 18-60 YearsCompletedNCT05846243Phase 2/3
- Safety and Tolerability Study of the VAC∆6 Vaccine in Volunteers Aged 18-40 YearsCompletedNCT05762523Phase 1
- Study to Assess the Safety and Immunogenicity of TPOXX® When Administered Orally for 28 Days With JYNNEOSActive, not recruitingNCT04957485Phase 2
- A Phase 4, Observational Field Study to Evaluate TPOXX in Patients With SmallpoxWithdrawnNCT03972111
- Post-licensure Department of Defense (DOD) Screening Accuracy Study in Military PersonnelCompletedNCT01540929
- Safety and Efficacy of CJ Smallpox Vaccine in Previously Vaccinated Healthy VolunteersCompletedNCT01317238Phase 3
- Safety and Efficacy of CJ Smallpox Vaccine in Healthy VolunteersCompletedNCT01056770Phase 3
- A Long-Term Study of Healthy Adults Vaccinated With One Dose of Smallpox Vaccine (LISTER Strain)CompletedNCT00998543
- Safety Surveillance Cohort Study of Vaccinia Vaccine (ACAM2000®)CompletedNCT00928577
- Safety Surveillance Study of ACAM2000® Vaccinia VaccineCompletedNCT00927719
- Poly-ICLC to Prevent Respiratory Viral Infections A Safety StudyCompletedNCT00646152Phase 1
- Safety, Reactogenicity and Immunogenicity of MVA in Hematopoietic Stem Cell Transplant (HSCT) SubjectsCompletedNCT00565929Phase 1
- Phase 2 Study of Safety, Tolerability, and Immunogenicity of Three Dose Levels of ACAM3000 Smallpox VaccineCompletedNCT00466245Phase 2
- Safety Study of MVA Smallpox Vaccine in Subjects With a History of Atopic Dermatitis (AD)WithdrawnNCT00389103Phase 1
- Safety and Immunogenicity of CJ-50300CompletedNCT00336635Phase 1
- Immune Responses to Smallpox VaccinationCompletedNCT00325975
- Safety Study of MVA Smallpox Vaccine in HIV-positive Subjects Who Are Vaccinia NaiveTerminatedNCT00282581Phase 1
- Evaluation of Take and Safety of a Smallpox Vaccine in Healthy Young AdultsCompletedNCT00258947Phase 2
- Take Rate, Immunogenicity and Safety of Elstree-BN Smallpox Vaccine in Healthy Vaccinia-Naive SubjectsCompletedNCT00189969Phase 1
- Dose-finding Study to Evaluate Immunogenicity of Three Different Dose Levels of the IMVAMUNE (MVA-BN) Smallpox Vaccine.CompletedNCT00189956Phase 2
- Study on Safety, Tolerability and Immunogenicity of an MVA Vaccine Administered to Healthy SubjectsCompletedNCT00189943Phase 1
- Safety, Tolerability and Immune Response of IMVAMUNE (MVA-BN)Smallpox Vaccine in Patients With Atopic DisordersCompletedNCT00189917Phase 1
- Safety, Tolerability and Immune Response of IMVAMUNE (MVA-BN)Smallpox Vaccine in HIV Infected PatientsCompletedNCT00189904Phase 1/2
- VHA Clinicians and Bioterror Events: Interactive Web-based LearningCompletedNCT00123396Not applicable
- Safety and Immunogenicity Study of LC16m8, a Modified Smallpox Vaccine, in Healthy, Previously Unvaccinated VolunteersStatus unknownNCT00103584Phase 1/2
- Combination Study With MVA BN and DryvaxCompletedNCT00082446Phase 1
- Safety, Tolerability, and Immune Response of ACAM3000 Modified Vaccinia Ankara (MVA) Smallpox Vaccine in AdultsCompletedNCT00079820Phase 1
- Human Immune Responses SmallpoxCompletedNCT00068198Phase 1
- Dressing Preparations for SmallpoxCompletedNCT00063856Phase 1/2
- Phase I/II Trial of Modified Vaccinia Virus Ankara (MVA) Vaccine Against SmallpoxCompletedNCT00053742Phase 1
- Dose Safety, Tolerability, and Immunogenicity of a New Smallpox Vaccine in Adults Without Previous Smallpox VaccinationTerminatedNCT00053508Phase 2
- APSV in Vaccinia Naive AdultsCompletedNCT00050518Phase 2
- Expanded Dryvax Dilution Study in Previously Vaccinated AdultsCompletedNCT00050505Phase 2
- Phase I Trial of Smallpox VaccineCompletedNCT00046397Phase 1
- Study of Reactogenicity, Safety, Immunogenicity, and Pock Lesion Formation of a Cell-Cultured Smallpox Vaccine Compared to Dryvax®CompletedNCT00042094Phase 1
- Vaccinia Virus Vaccine (APSV) in Vaccinia- Naive Subjects: PILOTCompletedNCT00038987Phase 1/2
- Dryvax Dilution-Prev Vacc AdultsCompletedNCT00032708Phase 2
- A Study of Dryvax Vaccine Against Smallpox in Previously Unvaccinated AdultsCompletedNCT00026611Phase 2
- A Comparative Phase I Clinical Study of HIVAC-1e and Smallpox (Vaccinia) Vaccines in Previously (Vaccinia) Vaccinated and Unvaccinated VolunteersCompletedNCT00002261Phase 1